Skip to content
value.today
Collegium Pharmaceutical Inc. logo

Collegium Pharmaceutical Inc.

Total raised
$77 M
4 rounds on record
Latest round
$50 M
Mar 2015
First round on record
Mar 2010
Today
Went public
See the company page

Collegium Pharmaceutical Inc. is listed today as Collegium Pharmaceutical, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Collegium Pharmaceutical Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$20 MPrivate placement after listing$10 to $50 million

Collegium Pharmaceutical Inc.: Private sale, Nov 2018

Investors in this round

1 investor had bought by the notice of Nov 13, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Collegium Pharmaceutical Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Virginia

People named in the notice

  • Alison B. Fleming · Executive Officer · Chief Technology Officer
  • Joseph Ciaffoni · Executive Officer, Director · President and Chief Executive Officer
  • Paul Brannelly · Executive Officer · Executive Vice President and Chief Financial Officer
  • Scott B. Dreyer · Executive Officer · Executive Vice President and Chief Commercial Officer
  • Shirley B. Kuhlmann · Executive Officer · Executive Vice President and General Counsel
  • David Hirsch · Director
  • Garen Bohlin · Director
  • Gino Santini · Director
  • Gwen A Melincoff · Director
  • John A Fallon · Director
  • John Freund · Director
  • Michael Heffernan · Director
  • Theodore A Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Brannelly, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 13, 2018. Read the notice at the SEC.

optionsSEC
Mar 2015$50 MNo. 4$50 to $250 million

Collegium Pharmaceutical Inc.: Raise no. 4, Mar 2015

Investors in this round

18 investors had bought by the notice of Mar 13, 2015: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Collegium Pharmaceutical Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Virginia

People named in the notice

  • Michael Heffernan · Executive Officer, Director
  • Paul Brannelly · Executive Officer
  • David Hirsch · Director
  • Eran Nadav · Director
  • Garen Bohlin · Director
  • Gino Santini · Director
  • John Freund · Director
  • Patrick Heron · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Heffernan, President. Source: SEC Form D, newest notice filed Mar 13, 2015. Read the notice at the SEC.

equitySEC
Aug 2013$4 MNo. 3$2 to $10 million

Collegium Pharmaceutical Inc.: Raise no. 3, Aug 2013

Investors in this round

13 investors had bought by the notice of Oct 2, 2013: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Collegium Pharmaceutical Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $12 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Heffernan · Executive Officer, Director
  • David W. Hirsch · Director
  • Gino W. Santini · Director
  • Patrick Heron · Director
  • Robert W. Jevon · Director
  • Stephen W. Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Heffernan, President. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC.

equitySEC
Feb 2012$22 MNo. 2$10 to $50 million

Collegium Pharmaceutical Inc.: Raise no. 2, Feb 2012

Investors in this round

12 investors had bought by the notice of Feb 24, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Collegium Pharmaceutical Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Heffernan · Executive Officer, Director
  • David Hirsch · Director
  • Patrick Fortune · Director
  • Patrick Heron · Director
  • Stephen Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Heffernan, President. Source: SEC Form D, newest notice filed Feb 24, 2012. Read the notice at the SEC.

equitySEC
Mar 2010$1 MNo. 1Under $2 million

Collegium Pharmaceutical Inc.: Raise no. 1, Mar 2010

Investors in this round

7 investors had bought by the notice of Mar 8, 2010: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Collegium Pharmaceutical Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Heffernan · Executive Officer, Director
  • Steven N. Tannenbaum · Executive Officer
  • Matthew N. Strobeck · Director
  • Patrick N. Fortune · Director
  • Patrick N. Heron · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven N. Tannenbaum, Executive Vice President. Source: SEC Form D, newest notice filed Mar 8, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Collegium Pharmaceutical, Inc., its revenue in fiscal 2025 came from these product and service lines: Belbuca $221.65 million (28%), Xtampza ER $199.31 million (26%), Jornay PM $148.86 million (19%), Nucynta IR $115.31 million (15%), Nucynta ER $80.98 million (10%).

    Annual report (SEC XBRL) · Dec 2025

  • Collegium Pharmaceutical Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2018

Products and services#

No products or services of Collegium Pharmaceutical Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Collegium Pharmaceutical Inc.
InvestorKindAmountRoundRoleSource
FHM VI, L.L.C.Othernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
FHM VI, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Frazier Healthcare VI, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Longitude Capital Associates, L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Longitude Capital Partners, LLCFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Longitude Venture Partners L.P.Venture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Skyline Venture Management V, LLCVenture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Skyline Venture Partners V LPVenture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 18 investors.

Largest shareholders today

Institutions holding Collegium Pharmaceutical, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Collegium Pharmaceutical Inc.
NameRoleNamed in
Alison B. FlemingChief Technology OfficerNov 2018
Joseph CiaffoniPresident and Chief Executive OfficerNov 2018
Paul BrannellyExecutive Vice President and Chief Financial OfficerNov 2018
Scott B. DreyerExecutive Vice President and Chief Commercial OfficerNov 2018
Shirley B. KuhlmannExecutive Vice President and General CounselNov 2018
Michael HeffernanExecutive officerMar 2015
Steven N. TannenbaumExecutive officerMar 2010
David HirschDirectorNov 2018
Garen BohlinDirectorNov 2018
Gino SantiniDirectorNov 2018
Gwen A MelincoffDirectorNov 2018
John A FallonDirectorNov 2018
John FreundDirectorNov 2018
Joseph CiaffoniPresident and Chief Executive OfficerNov 2018
Michael HeffernanDirectorNov 2018
Theodore A SchroederDirectorNov 2018
Eran NadavDirectorMar 2015
Patrick HeronDirectorMar 2015
David W. HirschDirectorOct 2013
Gino W. SantiniDirectorOct 2013
Robert W. JevonDirectorOct 2013
Stephen W. HoffmanDirectorOct 2013
Patrick FortuneDirectorFeb 2012
Stephen HoffmanDirectorFeb 2012
Matthew N. StrobeckDirectorMar 2010
Patrick N. FortuneDirectorMar 2010
Patrick N. HeronDirectorMar 2010

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.